Quarter Driven by Corporate Actions for NASDAQ Compliance and Building Operational Foundation for Long Term Growth Third quarter 2024 net loss of ($3.2) million compared to net loss of ($3.5) million for the prior year quarter, due to better gross margins Third quarter 2024 revenues of $7.7 million compared to $23.3 million for the prior…
Mattr Corp. Q3 2024 Earnings Conference Call Welcome to the Mattr Third Quarter 2024 Results Webcast On November 14, 2024, Mattr Corp. (OTCPK:MTTRF) held its Q3 2024 Earnings Conference Call at 9:00 AM ET. The conference call featured key company executives including Meghan MacEachern, VP of External Communications and ESG; Mike Reeves, President and CEO;…
Projects to Enhance Reliability for More Than 53,000 Customers in West Virginia and Maryland FAIRMONT, W.Va., Nov. 14, 2024 /PRNewswire/ — FirstEnergy Corp. (NYSE: FE) has been awarded $50 million in federal funding by the U.S. Department of Energy’s Grid Deployment Office for projects that will enhance electric service reliability for more than 53,000 Mon…
Bluebird bio, Inc. (NASDAQ:BLUE) recently held their Q3 2024 Earnings Conference Call on November 14, 2024, at 8:00 AM ET. The conference call included key company participants such as Courtney O’Leary, Director of Investor Relations, Andrew Obenshain, Chief Executive Officer, Tom Klima, Chief Commercial & Operating Officer, and James Sterling, Chief Financial Officer. Various analysts…
Feeling the Impact of GBP/USD Exchange Rate Movement Understanding the Current Market Situation GBP/USD eased further into the low end on Wednesday, trimming further south of the 200-day Exponential Moving Average (EMA) in a one-sided bearish decline as the pair closes in the red for a fourth consecutive trading day. The Pound Sterling shed extra…
Rhythm Pharmaceuticals Announces Positive Results from Phase 3 Trial for Rare Neuroendocrine Diseases Overview BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global biopharmaceutical company, has released data from its Phase 3 VENTURE trial. This study focused on setmelanotide, an MC4R agonist, in children aged 2 to under 5 with…
WidePoint Corporation Reports Strong Quarterly and Nine-Month Results FAIRFAX, VA / ACCESSWIRE / November 13, 2024 – WidePoint Corporation (NYSE American:WYY) has announced their latest financial results for the third quarter and nine-months ending September 30, 2024. Impressive Operational Highlights: • Won $15.2 million in contract awards and renewals, including $1.4 million in IT as…
Welcome to the Venus Concept Inc. Q3 2024 Earnings Conference Call Company Participants: Rajiv De Silva – Chief Executive Officer Hemanth Varghese – President and Chief Operating Officer Domenic Della Penna – Executive Vice President and Chief Financial Officer Conference Call Participants: Jeffrey Cohen – Ladenburg Thalmann Sam Eiber – BTIG Thomas McGovern – Maxim…
